In summary, METTL16 promotes CRC tumorigenesis and progression by coordinating metabolic reprogramming and mitotic regulation via m6A-dependent modulation of SOGA1, highlighting its potential as a prognostic biomarker and therapeutic target in CRC. This evidence concerns the gene MTCL2 and colorectal carcinoma.